Wassim Daoud Khatoun

@AlissaChebat Love you too ❤️

@WDKhatoun Love you! ❤️

Can’t be prouder!!

@ziremozay @YaleIMed @neerajaiims @umangtalking @montypal @maughanonc @NazliDizman @ReneeSaliby @huntsmancancer @nsayeghmd @ggebraelmd @LuisMezaco @ZeynepZengin @EbrahimiHedyeh @kor_shah @DrYukselUrun @osutcuoglu @BraunMDPhD Congrats Zeynep! Very well deserved

I’m going to Yale!! #Match2026 Still can’t believe I matched at my #1 choice @YaleIMed I'm so grateful to my mentors, friends, and family for supporting me every step of the way and believing in me! @neerajaiims @umangtalking @montypal @maughanonc @NazliDizman @ReneeSaliby

Pinch me!!! I’m going to be an OBGYN at my top choice @MethodistHosp 🌟 It truly takes a village and I’m endlessly grateful for the incredible support of my mentors, family, and friends 🩵 So excited for what’s ahead!!🤰🏻✨ #match2026 #obgyn

@MarcMachaalani @YaleIMed @DrChoueiri @BraunMDPhD @VincentWenxinXu @Clara__Steiner @eddy_saad @yekeduz_emre @ReneeSaliby @AminNassarMD @thenasheffect @TalalZarif1 Many congrats!! Very well deserved 👑

Thrilled to have matched at @YaleIMed! Beyond grateful to my amazing mentors, friends, and family for supporting me every step of the way! #Match2026

It truly takes a village! Thank you all!

Honored to continue to bring Colleagues more Great Science out of #GU26 & Sending Our Congratulations and gratitude to @ASCO for another Amazing meeting It is our Great Privilege to introduce One of our founding Faculty🚨 and dear friend Dr. Toni Choueiri of Dana farber🇺🇸discussing two Trials he was involved in: LITESPARK-022 Adding belzutifan to pembrolizumab for one year in patients with high-risk clear cell RCC after nephrectomy significantly improved disease-free survival, reducing the risk of recurrence or death by 28% (HR 0.72) compared with pembrolizumab alone. At 24 months, DFS rates were 80.7% versus 73.7%. The combination increased grade ≥3 adverse events, notably anemia, hypoxia, and liver enzyme elevations, but these were generally manageable with dose modification and supportive care. ARC-20 Evaluated casdatifan, a HIF-2α inhibitor, in heavily pretreated metastatic clear-cell RCC. Among 127 patients, objective response rate reached 31–35% with durable responses and median PFS up to 12.2 months. Deep, sustained serum erythropoietin reductions correlated with clinical benefit. Treatment was generally manageable, supporting phase 3 evaluation of casdatifan 100 mg daily. @DrChoueiri @motzermd @DrIacovelli @DrYukselUrun @elena_verzoni @tompowles1 @montypal @crisbergerot @DrDanielHeng @apolo_andrea @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @drenriquegrande @BraunMDPhD @cdanicas @brian_rini @AUC3_Official @nataliagandur @MarcMachaalani @Mustafajsalehmd @NazliDizman @DrYukselUrun @yekeduz_emre @WeiweiBian @ReneeSaliby @eddy_saad @Clara__Steiner @marc_eid @pablombarrios @WDKhatoun @Jad_El_Masri @lilli_ash @RashadNawfal @RazaneHChehade @elioibrahim8 @NafehGaelle @shaye_carver @zeyun_lu @SylvanBacaLab

What a great way to start the day at #ASCO #GU26— celebrating amazing posters presented this morning by colleagues and friends

Part of the @DanaFarber_GU team during #GU26 @DanaFarber @OncoAlert

Great presentation by Dr. David McDermott on the LITESPARK-024 part 1 (phase 1/2) dose-escalation belzutifan + palbociclib in heavily pretreated advanced ccRCC: - ORR: 21.1% (palbo 125 mg), DCR: 57.9-73.7% across dose levels - mPFS: 9.1 months at the full dose of palbo - DLTs: G3 anemia + G3 hypoxia (both at the highest dose) Safety profile was manageable, but a larger cohort is needed to better investigate the added benefit. #GU26 #RCC @OncoAlert

⭐️New era in adjuvant therapy for RCC @DrChoueiri presenting LS-022: Pembro+Belzutifan showing improved DFS vs Pembro (HR:072) Exciting for 2026 and beyond! #GU26 #ASCO @DrChoueiri @DanaFarber @OncoAlert

Very proud of @Mustafajsalehmd @DanaFarber_GU presenting our work with @SashaGusevPosts ! Super star in the making.

R3 LITESPARK-022: Adjuvant Pembrolizumab + Belzutifan vs Pembrolizumab for Clear Cell Renal Cell Carcinoma #GU26 showed significantly delayed DFS HR 0.72 (95% CI, 0.59–0.87) active across all subgroups. Immature OS (30 mnth OS 93% CDs 96%). ⬆️ Anaemia fatigue and transaminitis but only 4% discontinuation rate for belzutifan. The shape of the DFS curve and early OS trending the right way looks like initial analysis of KN564 and we know where that ended, making pem/bel attractive. @OncoAlert @DrChoueiri

Adjuvant pembrolizumab + belzutifan improved DFS vs pembrolizumab alone in high risk resected ccRCC. A meaningful step. Selection and follow up will be key. Proud to be an investigator in this milestone. @DrChoueiri @tompowles1 #gu26 #cancer #oncology #ASCO @oncoalert @ASCO @yekeduz_emre @CParkMD @OncBrothers @Larvol @nataliagandur @crisbergerot @ONCOassist @IMG_Oncologists

A little history recap: 2021: KN564 is positive 2024: KN564 shows the first OS improvement in adjuvant therapy in ANY type of cancer 2026: let's do better than KN564, pembro/bel > pembro @DrChoueiri

Once again @DrChoueiri delivers practice-changing data in ccRCC. In LITESPARK-022, adjuvant pembro+bel improved DFS vs pembro+placebo post-nephrectomy (HR 0.72, p=0.0003). Exceptional presentation by a great mentor! @ASCO #GU26 @DanaFarber @DanaFarber_GU @OncoAlert @urotoday

Phase 3 LITESPARK-011: Belzutifan + Lenvatinib vs Cabozantinib in pretreated metastatic clear cell renal cancer #GU25 shows +ve PFS HR 0.75 , OS HR 0.85 (non-significant), ⬆️ RR 53% vs 40%, G3+ TRAEs 72% vs 66%. Cabozantinib is hard to beat making this a standard of care. Using the most active drugs first rather than sequencing is debatable, but not all patients can sequence. We still don’t have significant OS post in IO refractory RCC @OncoAlert

@ImmunoBladder Dr. Molly Ingersoll highlights many hormonal and immunologic differences in women with #BladderCancer. Should we be developing gender specific biomarkers and therapies? @ASCO #GU26